Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.76 |
| ▸ | MMP1 | P03956 | 8/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7324083 | 0.86 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25209834 | 0.84 | HTT (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10154029 | 0.84 | L3MBTL1 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1001018 | 0.80 | HSD11B1 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7302796 | 0.80 | MMP1 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL10584023 | 0.79 | HSD11B1 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5602773 | 0.78 | MMP1 (1.00) | MMP1L3MBTL1HTTPOLBKMT2A | |
| SCHEMBL6915414 | 0.77 | ALDH1A1 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1161573 | 0.77 | HSD11B1 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9626048 | 0.77 | HSD11B1 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | claimed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | claimed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| EP-0968182-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | HDAC3 58/4885HDAC4 88/4885HDAC1 49/4885 |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | HELZ, MMEL1, GAA | HDAC3 157/4885HDAC4 275/4885HDAC1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.